Literature DB >> 21986127

High expression of CXCR4 and CXCR7 predicts poor survival in gallbladder cancer.

X Yao1, L Zhou, S Han, Y Chen.   

Abstract

Chemokine receptors play a prominent role in cancer progression and metastasis. This study investigated whether the expression of CXC chemokine receptor types 4 and 7 (CXCR4 and CXCR7, respectively), determined immunohistochemically, was associated with clinicopathological characteristics and postoperative survival in gallbladder cancer specimens from 72 patients. CXCR4 was detected in the cytoplasm and/or nucleus of gallbladder cancer cells, but CXCR7 was detected only in the cytoplasm. Expression of either CXCR7 or CXCR4 in the cytoplasm was associated with tumour stage. Expression of nuclear CXCR4 was associated with lymph node metastases and lymphatic invasion. Cytoplasmic expression of CXCR4 and CXCR7 were each independent risk factors for worse postoperative survival. Further research is required to clarify the mechanisms involved in these associations and to determine their potential prognostic and therapeutic implications.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21986127     DOI: 10.1177/147323001103900413

Source DB:  PubMed          Journal:  J Int Med Res        ISSN: 0300-0605            Impact factor:   1.671


  23 in total

1.  CXCL12-CXCR4/CXCR7 axis contributes to cell motilities of oral squamous cell carcinoma.

Authors:  Na Chen; Xiao Jiang; Juan Wang; Tong Wu; Bin Cheng; Juan Xia
Journal:  Tumour Biol       Date:  2015-08-02

2.  Expression of the Chemokine Receptors CXCR3, CXCR4, CXCR7 and Their Ligands in Rhabdomyosarcoma.

Authors:  Teresa San-Miguel; Sandra Pinto; Lara Navarro; Robert C Callaghan; Carlos Monteagudo; Concha López-Ginés; Miguel Cerdá-Nicolás; Rosario Gil-Benso
Journal:  Pathol Oncol Res       Date:  2015-06-03       Impact factor: 3.201

3.  C-X-C motif receptor 7 in gastrointestinal cancer.

Authors:  Hwan-Jung Yun; Hyewon Ryu; Yoon Seok Choi; Ik-Chan Song; Deog-Yeon Jo; Samyong Kim; Hyo Jin Lee
Journal:  Oncol Lett       Date:  2015-06-22       Impact factor: 2.967

4.  CXCR4 chemokine receptor signaling induces apoptosis in acute myeloid leukemia cells via regulation of the Bcl-2 family members Bcl-XL, Noxa, and Bak.

Authors:  Kimberly N Kremer; Kevin L Peterson; Paula A Schneider; X Wei Meng; Haiming Dai; Allan D Hess; B Douglas Smith; Christie Rodriguez-Ramirez; Judith E Karp; Scott H Kaufmann; Karen E Hedin
Journal:  J Biol Chem       Date:  2013-06-24       Impact factor: 5.157

5.  Adjuvant treatment in biliary tract cancer: to treat or not to treat?

Authors:  Stefano Cereda; Carmen Belli; Michele Reni
Journal:  World J Gastroenterol       Date:  2012-06-07       Impact factor: 5.742

6.  CXCL12 enhances human neural progenitor cell survival through a CXCR7- and CXCR4-mediated endocytotic signaling pathway.

Authors:  Bing Zhu; Dongsheng Xu; Xiaobei Deng; Qiang Chen; Yunlong Huang; Hui Peng; Yuju Li; Beibei Jia; Wallace B Thoreson; Wenjun Ding; Jianqing Ding; Lixia Zhao; Yi Wang; Kristin Leland Wavrin; Shumin Duan; Jialin Zheng
Journal:  Stem Cells       Date:  2012-11       Impact factor: 6.277

7.  High-level expression of CXCR4 in breast cancer is associated with early distant and bone metastases.

Authors:  Chin-Sheng Hung; Hou-Yu Su; Hung-Hwa Liang; Chieh-Wen Lai; Yo-Cheng Chang; Yuan-Soon Ho; Chih-Hsiung Wu; Jau-De Ho; Po-Li Wei; Yu-Jia Chang
Journal:  Tumour Biol       Date:  2013-10-08

Review 8.  Immune regulation by atypical chemokine receptors.

Authors:  Robert J B Nibbs; Gerard J Graham
Journal:  Nat Rev Immunol       Date:  2013-11       Impact factor: 53.106

Review 9.  CXCR4 over-expression and survival in cancer: a system review and meta-analysis.

Authors:  Hongli Zhao; Liyuan Guo; Hong Zhao; Jiaxin Zhao; Hao Weng; Bin Zhao
Journal:  Oncotarget       Date:  2015-03-10

Review 10.  A meta-analysis for CXCR4 as a prognostic marker and potential drug target in non-small cell lung cancer.

Authors:  Changyuan Zhang; Jie Li; Yi Han; Jian Jiang
Journal:  Drug Des Devel Ther       Date:  2015-06-24       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.